1. Introduction {#sec1-viruses-11-00392}
===============

Noroviruses are a highly prevalent pathogen associated with approximately 20% of diarrheal disease worldwide and are responsible for greater than 200,000 deaths each year \[[@B1-viruses-11-00392],[@B2-viruses-11-00392],[@B3-viruses-11-00392]\]. All age groups are susceptible to infection; however, the greatest incidence of disease occurs in children under the age of 5 years that can cause up to 70,000 deaths in children in developing countries. In healthy adults, the disease is usually self-limiting and only rarely becomes problematic. However, in the immunocompromised (all ages) and in the elderly with underlying health problems and immunosenescence, mortality becomes higher \[[@B2-viruses-11-00392],[@B4-viruses-11-00392]\]. In addition to the effect on individual health, the worldwide economic burden of norovirus disease is estimated to be approximately 60 billion dollars per year \[[@B5-viruses-11-00392]\]. As the understanding of the prevalence and burden of norovirus disease strengthens, the need for preventative and therapeutic measures becomes more apparent, including the development of an effective vaccine \[[@B6-viruses-11-00392],[@B7-viruses-11-00392]\].

One of the interesting features of norovirus disease, but one that is difficult to address for vaccine development, is the large number of different genotypes, and the multiple strains within each genotype, that circulate in the human population \[[@B6-viruses-11-00392],[@B8-viruses-11-00392]\]. There are three genogroups of norovirus that can infect humans, which include Genogroups I, II, and IV, although the GI and GII viruses are the major causes of human disease. Within each of the GI and GII genogroups there are many genotypes, of which the GII.4 genotype noroviruses are of particular importance because of their higher incidence and their association with more severe disease \[[@B8-viruses-11-00392],[@B9-viruses-11-00392]\]. The GII.4 noroviruses are unique in their continuous evolution and cyclic emergence of new pandemic strains that may avoid the existing immunity in the population \[[@B10-viruses-11-00392],[@B11-viruses-11-00392]\]. For a norovirus vaccine to be highly efficacious it must be able to protect against the GII.4 strains in circulation and ideally, newly emerged GII.4 strains. The other norovirus genotypes appear to have a more stable evolution and show few changes in sequence over time, although they do remain in circulation and contribute to a significant portion of the norovirus infections \[[@B8-viruses-11-00392],[@B12-viruses-11-00392]\]. Non-GII.4 noroviruses may be responsible for additional outbreaks, and the specific genotypes responsible can vary. A major challenge in norovirus vaccine development is to prepare formulations to elicit cross-reactive antibody responses capable of broad neutralization of multiple genotypes.

A major roadblock in norovirus research has been the lack of a suitable culture system that would allow in vitro growth and replication of the virus. Because of this, two common vaccine platforms---attenuated or killed viral vaccines---have not been available for the development of norovirus vaccines. The discovery of virus-like particles (VLPs) for norovirus and their application to the area has been critical in advancing the understanding of norovirus disease and the development of methodologies to characterize immune responses \[[@B13-viruses-11-00392]\]. VLPs are generated by the expression of the viral capsid protein VP1 in cell culture, which can self-assemble to structures that mimic the virus particles. VLPs are believed to reproduce many features of the virus and have been used to study the structure and function of norovirus. Norovirus VLPs have also been shown to be antigenic and most vaccine candidates are based on different variations of VLPs \[[@B6-viruses-11-00392],[@B7-viruses-11-00392],[@B14-viruses-11-00392],[@B15-viruses-11-00392],[@B16-viruses-11-00392],[@B17-viruses-11-00392],[@B18-viruses-11-00392]\]. Candidate vaccines have been composed of purified VLPs or P-particles that express the protruding domain of the VP1 protein. Other vaccines have employed vectors that express VP1 proteins that would generate VLPs after delivery of the vaccine. Multivalent formulations of VLPs or chimeric VLPs have also been tested to address the breadth of coverage needed for a norovirus vaccine. Takeda Vaccines has been developing a bivalent VLP-based vaccine against norovirus that includes one VLP representing each of the major genogroups. The genogroup I VLP is based on the Norwalk virus---the first identified norovirus---and is genotype GI.1. The second VLP is a "consensus" GII.4 VLP made by combining sequences from the Houston (2002), Yerseke (2006) and DenHaag (2006) GII.4 strains \[[@B19-viruses-11-00392],[@B20-viruses-11-00392]\].

To evaluate vaccine efficacy, measurement of immune responses to the vaccine is needed with preference for functional assays that may better relate to efficacy than an assay based solely on antibody binding \[[@B21-viruses-11-00392]\]. For vaccines against viruses, neutralization assays are most commonly used as the functional assay for measurement of antibodies that stop or neutralize viruses from infecting cells. Norovirus infection systems have only recently become available \[[@B22-viruses-11-00392],[@B23-viruses-11-00392]\], but these infection models are still highly variable and are not yet suitable to establish neutralization assays with the reproducibility and reliability needed for the routine sample testing, although they have been valuable to characterize neutralizing human monoclonal antibodies \[[@B24-viruses-11-00392]\]. Blockade assays have been an extremely valuable surrogate for virus neutralization assays and these assays use norovirus VLPs as substitutes for whole virus, and measure the ability of serum antibodies to block the binding of the VLPs to cell surface carbohydrates \[[@B25-viruses-11-00392],[@B26-viruses-11-00392]\]. Noroviruses interact with cell surface carbohydrates, such as the Histo-Blood Group Antigens (HBGAs) that have been identified as important attachment factors for norovirus \[[@B27-viruses-11-00392],[@B28-viruses-11-00392]\]. The ability of antibodies to block attachment of VLPs is considered a functional activity, and blocking antibodies have been found to be a correlate with protection in human infection and challenge models \[[@B29-viruses-11-00392],[@B30-viruses-11-00392],[@B31-viruses-11-00392],[@B32-viruses-11-00392]\]. To measure blockade antibodies, synthetic HBGAs and salivary mucins can be used as the carbohydrate substrates. However, these reagents have considerable variability and only a limited range of VLPs show binding to each type. The use of pig gastric mucin (PGM), which contains several human HBGAs, as the substrate for VLP binding has been invaluable in enhancing reproducibility and the range of VLPs that bind \[[@B31-viruses-11-00392]\], and PGM is the substrate of choice for the blockade assays described in this paper.

The Takeda TAK-214 norovirus vaccine has been found to be safe and immunogenic in several human clinical trials \[[@B20-viruses-11-00392],[@B33-viruses-11-00392],[@B34-viruses-11-00392],[@B35-viruses-11-00392]\]. To gain a better understanding of the capabilities of the vaccine, the magnitude and breadth of blocking antibodies that are elicited, or boosted, by the vaccine need to be characterized. This requires many different VLP blockade assays because of the large number of norovirus genotypes that circulate. Since each VLP has its own unique characteristics, a rigorous optimization is needed to develop reliable assays for each VLP. The work described here illustrates several parameters that were key to the optimization of blockade assays for 20 different norovirus VLPs. Screening of adult human sera using the established blockade assays showed a complex repertoire of blocking responses, before and in response to vaccination. The blockade assays optimized for a large VLP panel will be important to delineate the immune responses to noroviruses, and to help identify those responses that may be protective against disease.

2. Materials and Methods {#sec2-viruses-11-00392}
========================

2.1. Assay Buffers {#sec2dot1-viruses-11-00392}
------------------

Phosphate buffers (100 mM) with different pH values were prepared by mixing ratios of the stock 100 mM monobasic (NaH~2~HPO~4~, Thermo Fisher Scientific, Waltham, MA, USA) and dibasic (Na~2~HPO~4~, Thermo Fisher Scientific, Waltham, MA, USA) solutions, to generate the desired pH. If needed NaCl (Sigma-Aldrich, Natick USA) was then added to 150 mM from a 5 M stock and Tween 20 (Thermo Fisher Scientific, Waltham, MA, USA) added to 0.05%. The final pH was adjusted by adding either the monobasic or dibasic stock.

2.2. Production of VLPs {#sec2dot2-viruses-11-00392}
-----------------------

VP1 amino acid sequences obtained from GenBank were used to commercially synthesize a mammalian codon optimized nucleotide gene sequence for each particular VP1 protein (ATUM, Newark USA). The GenBank Accession numbers for all VLPs are listed in [Table A1](#viruses-11-00392-t0A1){ref-type="table"}. Restriction sites were engineered onto the ends of the synthetic genes to facilitate cloning into the AdEasy Adenoviral Vector System Cloning kit from Agilent that was used to produce the recombinant adenovirus clones. The recombinant adenoviruses were used to infect Vero cells at a multiplicity of infection of 300, and cultures were harvested after 4 days. The supernatant from cells was removed and the adherent cells were treated with a PBS and 0.1% Tween solution for 5 min with rocking at room temperature to lyse cells. The lysate was clarified by centrifugation (400× *g*) and filtered through a 0.45 µM syringe filter and then spun into a 40% sucrose cushion in an ultracentrifuge (100,000× *g*) as described elsewhere \[[@B36-viruses-11-00392]\]. Purity of VLPs was assessed by SDS-PAGE and concentration determined by BCA assay. The VLPs were frozen at −80 °C in the 40% sucrose/PBS buffer and used in blockade assays by dilution into assay buffer. Once thawed, VLPs were stored at 4 °C for up to one year or until loss of PGM binding was evident. The vaccine antigen VLPs GI.1 and GII.4 CN are the only two VLPs not made by expression in mammalian cells. These VLPs were obtained from manufacturing runs of vaccine VLPs that are produced in insect cells using a baculovirus expression system.

2.3. Detection Antibodies {#sec2dot3-viruses-11-00392}
-------------------------

VLP specific antibodies were generated by injecting rabbits with purified VLPs using Gerbu Adjuvants^®^ (GERBU Biochemicals GmbH, Gaiberg, Germany) to generate hyperimmune serum. Sera from 3 rabbits were pooled and the IgG fraction was purified. The purified IgG was used as the detection antibody in the PGM binding and blockade assays. [Table A1](#viruses-11-00392-t0A1){ref-type="table"} lists the different detection sera used and working concentrations for VLPs and antibodies for the different assays.

2.4. Human Serum Samples {#sec2dot4-viruses-11-00392}
------------------------

Unvaccinated human sera (individual or pooled) were obtained from several commercial sources (Sigma-Aldrich, Natick USA; BioIV, Westbury USA; Innovative Research, Novi USA; Jackson ImmunoResearch, West Grove USA). These adult human sera were evaluated for blocking activity against the panel of VLPs to identify those with positive blockade responses for optimization experiments.

Clinical trial samples were obtained under written informed patient consent from two clinical trials NOR-201 (NCT02142504; IRB00000231 Cincinnati (FWA00002988), IRB00000773 San Diego (FWA00006704), IRB00003226 San Francisco (FWA00008684) Coral Gables (FWA00018376) Rochester (FWA00001317) Austin (FWA00008684), IRB00000158 St. Louis (FWA0005304), IRB00000533 Rochester (FWA00009386), IRB00000077 Houston (FWA00000286)) and NOR-210 (NCT02475278; IRB00003226 Austin (FWA00008684)). Samples were selected from individuals who were given the selected adult dose for TAK-214; a vaccine dose of 15 µg GI.1, 50 µg GII.4CN, and 500 µg Aluminum hydroxide (Al(OH~3~). Subjects in the NOR-201 trial were administered a vaccine that contained 50 µg Monophosphoryl Lipid A (MPL) per dose in addition to the VLPs and Al(OH~3~) amounts noted above. Samples from both trials included pre-bleeds and samples taken approximately 30 days after a single dose of vaccine. Both trials were conducted in subjects 18 to 49 years of age in North America. Samples from 25 subjects were obtained from participants in the NOR-201 trial conducted in 2014. Samples from 24 subjects were obtained from participants in the NOR-210 trial conducted in 2015.

2.5. Pig Gastric Mucin (PGM) Coated Plates {#sec2dot5-viruses-11-00392}
------------------------------------------

NUNC 96-well plate flat bottom Maxisorp plates (Thermo Fisher Scientific, Waltham, MA, USA) were coated with 100 µL of a 5 µg/mL solution of PGM (Sigma-Aldrich, Natick, MA, USA) in PBS (Thermo Fisher Scientific, Waltham, MA, USA) overnight at 4 °C, or 1 h at 37 °C. Following coating, plates were washed 3 times with 300 µL/well PBS and 0.05% Tween 20 (PBST), and then blocked with 200 µL/well of StartingBlock (PBS) Blocking Buffer (Thermo Fisher Scientific, Waltham, MA, USA) for 1 h at room temperature. Plates were washed 3 times with PBST before use.

PGM contains several human HBGAs that are bound by VLPs, but does not contain the Blood Group B antigen which is recognized by GII.12 noroviruses, and GII.12 VLPs do not bind PGM coated plates \[[@B30-viruses-11-00392],[@B37-viruses-11-00392],[@B38-viruses-11-00392]\]. Blood group H antigen found in PGM can be converted to B antigen using the enzyme, B antigen glycosyl transferase (GTB). Conditions were developed in which the blocked PGM coated plates were treated with recombinant human blood group B transferase/GTB Protein (R&D Systems, Minneapolis, MN, USA) to generate B antigen (manuscript in preparation). For this, blocked PGM coated plates were incubated with 0.25 µg/mL GTB protein in assay buffer (50 mM HEPES pH 6.5, 1.5 mM UDP-galactose, 5 mM MnCl~2~) for 6 h at 37 °C. Plates were washed 3 times and 150 µL PBST was added to each well and held overnight at 4 °C before use. The GII.12 (2010) VLP binds to PGM plates treated with GTB, and these GTB treated PGM plates are used for the GII.12 VLP blockade assay.

2.6. Immunological Assays {#sec2dot6-viruses-11-00392}
-------------------------

The PGM binding assay was performed by adding VLPs to blocked PGM-coated plates and incubating for 1 h at 22 °C or 37 °C. Following 3 washes with PBST, detection antibody specific for the VLP diluted in assay buffer was added and the plates were incubated at room temperature for 1 h and then washed 3 times with PBST. A goat anti-rabbit IgG-HRP (Southern Biotech, Birmingham, AL, USA; \#4030-05) secondary antibody was then added at 1:3000 dilution in assay buffer and incubated for a further 1 h at room temperature. Following 3 washes, enzyme substrate (ABTS Peroxidase Substrate, KPL) was added and allowed to react for 12 min at room temperature. ABTS Peroxidase Stop Solution (KPL) was then added and plates were read at a wavelength of 450 nM in a Molecular Devices plate reader using SoftMax Pro Software (Molecular Devices, Downingtown, PA, USA) to obtain the Optical Density (OD) of each well.

For blockade assays performed on the clinical samples, samples were first diluted 1:15 in assay buffer and added to 96-well dilution plates (NUNC, conical bottom non-stick plates) and serially diluted 4-fold down the plate. A positive serum control and a VLP-only control were run in columns 11 and 12 respectively. Following the dilution step, VLP diluted to 2× in assay buffer was added to the dilution plate in 100 µL bringing the total volume in each well to 200 µL. The plates were sealed and incubated for 18 h in an environmental chamber set at 22 °C. The following day 150 µL of the solution from the dilution plate was transferred to the PGM coated plate and the remaining steps followed those of the PGM binding assay described above. The OD data was curve fit using the Log-Logit function in SoftMax pro. Blocking titers were calculated as the serum dilution interpolated at ½ the maximum OD for that plate and represents the serum dilution that produces a 50% reduction in VLP binding to PGM. The maximum OD for the plate was calculated from the VLP only column. The background of the assay was assigned a titer of 30 which is the starting dilution of the sera. Any samples with titers below 30 were given a value of \<30 and assigned a value of 15 for performing calculations. Statistical analyses of the data were performed using Microsoft Excel and GraphPad Prism (GraphPad, San Diego, CA, USA).

For testing clinical samples, to reduce variability, all samples were tested on the same day, by the same operator for each individual blockade assay (10 plates total). The pre- and postvaccination samples were run on the same plate, to also reduce possible variability. To conserve serum and support the many assays performed on each sample, and because of the low variability found between duplicate curves in the optimized assays, samples were run as single dilution curves. Positive controls, also run as single dilution curves, were tested on each plate during the sample testing and were used to monitor the assays. The overall variability in positive controls values measured during the testing was approximately 10% CV (standard deviation/mean − 100) indicating that the between assay variability was low.

### 2.6.1. Optimization of PGM Binding {#sec2dot6dot1-viruses-11-00392}

A screening procedure was developed to identify conditions for optimal binding of each VLP to PGM following an overnight incubation in buffer to mimic the conditions used for the blockade assays. The 96-well dilution plates were set up with 4 wells to test each condition and the ODs measured in the 4 replicate wells were averaged to compare conditions. VLPs were incubated in 200 µL of phosphate assay buffers of different pH (pH 6.5, 7.0, and 7.5) with and without 5% skim milk for 18 h at 22 °C without antibody. The following morning, 150 µL of the solutions were transferred to the PGM coated plates and the assay completed as described above. The OD values indicated the strength and overnight stability of VLP binding to PGM.

### 2.6.2. Optimization of Blockade Assays {#sec2dot6dot2-viruses-11-00392}

Once buffer conditions were evaluated for each VLP, a final set of experiments were performed to optimize the assay conditions to maximize the sensitivity for measuring blocking antibodies. Commercial human sera (negative and 3 positives with a range of strengths for each VLP blockade assay) were screened under different conditions: buffer pH (6.5 and 7.5), primary incubation (18 h and 1 h), and PGM binding temperature (22 °C and 37 °C). For each serum and condition combination, a titer was calculated. If low binding of the VLP to PGM occurred under any of the conditions (less than half of the optimal binding OD) that condition was designated as "failed" and titers were not calculated. This ensured that the titers were calculated from binding curves with sufficient magnitude and reliable curves. For each of the 3 positive sera, titers were used to generate a ratio of titers measured under the two conditions being compared to assess which condition generated the highest titers.

3. Results {#sec3-viruses-11-00392}
==========

3.1. Optimal Conditions for Blockade Panel {#sec3dot1-viruses-11-00392}
------------------------------------------

Previous development of a GII.4 (2012) Sydney blockade assay in our laboratory had identified several parameters that greatly improved the measurement of blocking antibodies. The conditions with most impact were an overnight incubation of VLP with antibody at 22 °C, conducting the PGM binding incubation at 37 °C, and the use of VLPs expressed in mammalian cells. For this work, the buffer was PBS (pH 7.4) with Tween 20 (0.5%) and 5% skim milk.

As more VLPs were generated for use in the blockade assay panel, several VLPs were found not to work well in the conditions used for the GII.4 (2012) assay. A more comprehensive evaluation of optimal assay conditions was therefore required for the extended VLP panel.

### 3.1.1. Buffer Evaluation {#sec3dot1dot1-viruses-11-00392}

The PGM binding activity of VLPs was addressed with a screening procedure that evaluated buffer pH (6.5, 7.0, and 7.5), the presence or absence of 5% skim milk and incubation temperature for PGM binding (22 °C or 37 °C) as described in the Materials and Methods. The average OD measured in 4 replicate wells was used to calculate the relative strength of binding under the different conditions. The strongest binding (highest OD) was assigned a value of 100%. [Table 1](#viruses-11-00392-t001){ref-type="table"} lists the results across a panel of different VLPs with shading in red representing the strongest binding and in green the weakest binding.

Several general characteristics of VLP binding are apparent in [Table 1](#viruses-11-00392-t001){ref-type="table"} and these were used to identify conditions of most importance to guide the optimizing of the blockade assays themselves.

The presence of 5% skim milk reduced the binding of all VLPs under all conditions, with the only exception being the binding of GII.4 CN at pH 7.5 and incubation at 37 °C. In some cases, the presence of skim milk very strongly inhibits binding (see GI.4 VLP). Skim milk is commonly used in plate-based assays to reduce nonspecific binding, but it is a complex uncharacterized component that can ideally be removed from buffers when assays advance towards routine testing. Glycans found in human milk have been found to bind to norovirus VLPs and block association with HBGAs \[[@B39-viruses-11-00392]\], thus inhibitory glycans may also be present in skim milk products. Based on the buffer investigations, the 5% skim milk was removed as a buffer component since it selectively influences binding of VLPs to PGM. To reduce nonspecific binding to the plates in the absence of skim milk, a commercial blocker was used to block the PGM-coated plates prior to their use.

In [Table 1](#viruses-11-00392-t001){ref-type="table"}, there is also a noticeable trend for the strongest binding for the majority of the VLPs to occur at a pH of 6.5, although several VLPs bound well across the range of assay buffer pHs. Notably, all the VLPs that had poor binding at pH 7.5 showed improved binding at pH 6.5 (e.g., GI.5 and GII.4 CN). This finding was helpful in addressing the inconsistent binding behavior of several VLPs in the original pH 7.4 buffers. Problems with variability in blockade assays were found to be most often resolved by lowering the assay buffer to pH 6.5. Because the pH 7.0 buffer does not appear to offer any additional advantage over the binding found in either the pH 6.5 or 7.5 buffers, it was not included in the subsequent optimization of the blockade assays.

One final trend of interest was that binding to PGM at 37 °C generally produced the highest binding with typically a 10--20% improvement over binding at 22 °C. However, for some VLPs under nonoptimal buffer conditions there was actually a reduction in binding at 37 °C (see GI.5, GII.4 CN, and GII.17 1978). This apparent sensitivity to temperature is not related to the stability of the VLPs, but rather appears to be related to the strength of the VLP interaction with PGM. Two of the VLPs (GI.6 and GIV.1) were found to show strongest PGM binding at 22 °C irrespective of the buffer, and therefore the PGM binding step in blockade assays with these VLPs are performed at 22 °C (see below).

### 3.1.2. Blockade Assay Optimization {#sec3dot1dot2-viruses-11-00392}

Based on the results of the assay buffer evaluation, the optimization of VLP blockade assays was carried out by comparing test results obtained under different conditions of primary incubation (18 h and 1 h), PGM binding temperature (22 °C and 37 °C) and assay buffer pH (6.5 and 7.5). This final optimization was needed to identify conditions that measured the blocking titers with the most sensitivity and reliability, rather than just selecting best conditions based on VLP binding, since stronger binding to PGM could actually reduce sensitivity of the blockade assays. For these investigations commercially obtained human sera were used. Unvaccinated human serum has a mixture of anti-norovirus antibodies from past exposures that should also contain cross-reactive antibody populations, which are an important population for the blockade assay panel to capture.

Human sera (individual and pooled) were screened to identify sera that were negative, or with high, medium and low titer for each of the VLP blockade assays. As described in the Material Methods section, the sera were then tested under a variety of conditions and the corresponding titers were used to identify the preferred conditions for measuring blocking activity. [Table 2](#viruses-11-00392-t002){ref-type="table"} summarizes these investigations and lists the outcomes and the final conditions selected for each of the assays. The data in [Table 2](#viruses-11-00392-t002){ref-type="table"} is a summary of 640 individual tests and illustrates the considerable effort undertaken to verify and optimize these assays. The ratios listed in [Table 2](#viruses-11-00392-t002){ref-type="table"} are used as an indication of the best conditions to obtain the most sensitive measurement of blockade titers. Ratios over 1 indicate the numerator condition is the optimal condition. Cells that list either "37°C Fail" or "pH 7.5 Fail" are situations where the VLP binding to the PGM was below a predetermined minimum value and these data were not used in the calculations. The final two columns in the table list the assay conditions selected for each of the different blockade assays.

For the primary incubation all calculated ratios were above 1, indicating that the 18h incubation in general was the best condition for all blockade assays. In no case was the titer measured following 18 h incubation lower than using 1h incubation, although usually the titers were the same under these conditions, especially with higher titer sera. The 18 h incubation does not raise the assay background and did not convert any of the negative responses to positive, indicating that the enhancement is specific. In past experiments, some sera and monoclonal antibodies have been found to be greatly influenced by the longer incubation time and titers up to 10-fold higher are generated under the longer incubation time. For this reason, the 18 h incubation is preferred as it may best capture the binding of all different antibody populations. The 18 h incubation may allow binding to hidden epitopes as found for West Nile Virus neutralization studies \[[@B40-viruses-11-00392]\] where "breathing" of the particle may allow antibodies to interact with the occluded sites. Using a higher temperature for the primary incubation may also have a similar effect \[[@B10-viruses-11-00392],[@B41-viruses-11-00392]\], however, the 18 h incubation was chosen as it is logistically simpler to divide the lengthy blockade assays over two days especially when large numbers of samples are being tested. Using an extended time for the primary incubation has also been used in qualified assays that have been used to measure responses for human vaccine clinical trials \[[@B42-viruses-11-00392],[@B43-viruses-11-00392]\].

For the PGM incubation step listed in [Table 2](#viruses-11-00392-t002){ref-type="table"}, GI.6 and GIV.1 assays are listed as failing at higher temperature which is a result of their poor binding to PGM at 37 °C. Under these conditions titers were not calculated since proper binding curves could not be generated from the low OD values. These two assays are therefore performed at 22 °C since they are unreliable at higher temperature. For VLPs that bind well to PGM at 37 °C, the PGM incubation step in the blockade assays all had ratios above 1 indicating that the higher temperature slightly increased sensitivity and higher titers were obtained.

The third condition to be evaluated and summarized in [Table 2](#viruses-11-00392-t002){ref-type="table"} was the assay buffer pH. Although binding at pH 6.5 appeared to be a reasonable condition for all VLPs, the data indicate that for measuring titers, this may not be the optimal pH. This is especially apparent for the GII.17 and GII.4 strains that have ratios less than 1. The GII.17 blockade assays, for example, have ratios near 0.5 indicating that titers measured at pH 7.5 are about twice those measured at pH 6.5. In general, pH 7.5 may be most sensitive for measuring blocking titers, however, the large number of VLPs that have unreliable binding at that pH (listed as pH 7.5 fail) must be tested at pH 6.5 to generate consistent outcomes.

Although no universal assay conditions could be found that worked for all assays, a set of 3 assays have been established; pH 6.5 buffer with 37 °C PGM binding, pH 6.5 buffer with 22 °C PGM binding, and pH 7.5 buffer with 37 °C PGM binding step. All other conditions for the assays are the same.

3.2. Testing of Samples from Individuals Vaccinated in Clinical Trials {#sec3dot2-viruses-11-00392}
----------------------------------------------------------------------

The final optimized conditions for each of the blockade assays were used to analyze samples selected from two Takeda clinical trials for comparison of antibody responses in subjects pre- and postvaccination, and the influence of inclusion of the MPL adjuvant on the response to vaccine.

[Table A2](#viruses-11-00392-t0A2){ref-type="table"} and [Table A3](#viruses-11-00392-t0A3){ref-type="table"} in the appendix list the blockade titers measured in serum from subjects before and after vaccination with the TAK-214 vaccine. Samples selected from the NOR-201 study were from subjects who received the vaccine formulated with MPL, while all the samples from the NOR-210 study were from subjects vaccinated with a formulation that did not include MPL. Assessing the effects of vaccination in a primed population with different exposure histories is not simple and several different approaches have therefore been used to help fully describe the dataset.

As an initial assessment of the blockade data, the percent of responses above the assay background of 30 ([Table 3](#viruses-11-00392-t003){ref-type="table"}) and the geometric mean titers (GMTs) ([Table 4](#viruses-11-00392-t004){ref-type="table"}) were tallied and compared across the assay panel. [Table 3](#viruses-11-00392-t003){ref-type="table"} lists the percentage of individuals with blockade responses above background for each of the VLPs pre- and postvaccination. Data are listed separately for each trial and for both trials combined. These measures give an indication of the breadth of the responses, but not necessarily the magnitude. [Table 4](#viruses-11-00392-t004){ref-type="table"} lists the calculated GMTs in the same arrangement as [Table 3](#viruses-11-00392-t003){ref-type="table"}, and is an indicator of the magnitude of the response across the different populations.

### 3.2.1. Preexisting Responses {#sec3dot2dot1-viruses-11-00392}

The breadth and magnitude of the preexisting responses would be influenced by the genotypes that had circulated in these populations prior to the trials. The higher percentage of positives and higher GMTs for the GII.4 strains in both NOR-201 and NOR-210 clinical trials agrees with the prevalence of this genotype. As listed in [Table 3](#viruses-11-00392-t003){ref-type="table"} and [Table 4](#viruses-11-00392-t004){ref-type="table"}, the NOR-201 and NOR-211 trials had similar patterns of preexisting immune responses. Both trials were run in the United States, in the same age group, and within two years of each other, so large differences were not expected. The only difference of note is the consistent lower number and magnitude of preexisting responses to GII.4 in NOR-210. This difference may be due to the sporadic nature of norovirus outbreaks where differences may be expected from one location to another. There were 10 clinical sites in NOR-201 but only a single site in NOR-210.

Within the preexisting measured responses, some reactivity was found to all the VLPs tested. This likely reflects both the response to infection by specific norovirus strains of which a high number remain in circulation, and cross-reactive responses between the strains. Among the individual subjects in the trials, there was great variability in the number of positive preexisting responses. One individual had no positive responses, and another was positive to all 13 genotypes tested ([Table A2](#viruses-11-00392-t0A2){ref-type="table"} and [Table A3](#viruses-11-00392-t0A3){ref-type="table"}), and the average number of positive preexisting responses per subject was 6.

### 3.2.2 Postvaccination Responses {#sec3dot2dot2-viruses-11-00392}

Evaluation of percent postvaccination positive responses showed that 90% and 100% of individuals were positive to the vaccine antigens GI.1 and GII.4 CN, respectively. This is as expected, as TAK-214 generates strong immune responses to the vaccine antigens. Additionally, since GII.4 CN is a mixture of sequences from the GII.4 2002, 2006a, and 2006b strains, these VLPs are also expected to show enhanced blocking antibodies postvaccination. There was also a general boost of positive responses and GMTs to all the VLP genotypes. This will be explored in more detail in the following sections; however, these data indicate that vaccination can boost responses against genotypes outside of the vaccine strains. This general boosting of the breadth is also reflected in the number of positive responses per individual with the average now climbing to 9.

### 3.2.3 Role of MPL {#sec3dot2dot3-viruses-11-00392}

One goal of this work was to look further into the possible role of MPL for enhancing the activity of TAK-214. Previous work had found that there was no evidence that MPL enhanced the magnitude of immune responses when it was included in the vaccine formulation, and this work was intended to see if any impact on the breadth of responses was apparent using MPL. All samples tested from the NOR-201 trial had been from individuals given vaccine containing MPL, whereas subjects in the NOR-210 only received vaccine without MPL. Comparing the results between these trials ([Table 3](#viruses-11-00392-t003){ref-type="table"}, [Table 4](#viruses-11-00392-t004){ref-type="table"} and [Table 5](#viruses-11-00392-t005){ref-type="table"}) indicates that no real differences existed in the responses to vaccines with, or without, MPL. Averaging outcomes across the assays showed that the percentage of positive individuals was the same (79%) in both trials after vaccination, and the GMT and fold-rises were actually slightly higher in the NOR-210 trial (628 versus 467, and 5.7 versus 4.2, respectively). These results indicate that the magnitude and breadth of responses did not differ significantly when MPL was included in the vaccine formulation.

### 3.2.4 Geometric Mean Fold-Rise of Blockade Titers {#sec3dot2dot4-viruses-11-00392}

Another method to evaluate the effect of vaccination is to examine the geometric mean fold rise (GMFR) in blockade titers. [Table 5](#viruses-11-00392-t005){ref-type="table"} lists the fold increases measured for blocking antibodies against the different VLP strains. The two trials are once again shown separately and in combination.

In general, vaccination increased antibodies to all antigens tested. Vaccination elicited a greater than 4-fold increase in GMFR against the vaccine antigens (GI.1 and GII.4 CN), as well as nonvaccine antigens such as GI.5, GI.6, GII.4 (2009), and GII.4 (2012). Although the magnitude of the rise in antibodies was comparable for several assays, the character of the boosting among the individual subjects differed. To better illustrate these differences, [Figure 1](#viruses-11-00392-f001){ref-type="fig"} and [Figure 2](#viruses-11-00392-f002){ref-type="fig"} below track the individual subjects and their responses before and after vaccination for several of the VLPs. The responses have been categorized into those with high GMFRs and those with low GMFRs.

3.3. High GMFR Responses {#sec3dot3-viruses-11-00392}
------------------------

VLPs with blockade responses that displayed high GMFRs showed a broad boosting of responses across virtually all individuals irrespective of their preexisting responses, and a strong increase in the overall GMT of the population ([Figure 1](#viruses-11-00392-f001){ref-type="fig"}).

The Norwalk virus (GI.1) was the first strain of norovirus discovered and still circulates to the present day, although at a low level, and this is reflected in the low number of individuals categorized as having a positive response before vaccination. After vaccination, most individuals did show positive responses indicating a strong vaccine-antigen specific response as found previously in human trials.

In contrast to the Norwalk strain, the GII.4 strains of norovirus are the most common currently in circulation. Therefore, as expected, the number of individuals with positive preexisting responses was much higher for GII.4 CN than to GI.1. [Figure 1](#viruses-11-00392-f001){ref-type="fig"} also shows that all individuals responded to vaccination against the vaccine GII.4 antigen. The larger fold-rise measured in the NOR-210 samples was mainly a result of the lower preexisting titers in this group as noted previously.

One critical feature needed for a norovirus vaccine is the coverage of immune response across the various strains of the GII.4 genotype because of their predominance in causing norovirus disease. The GII.4 (2012) Sydney strain emerged after the GII.4 CN antigen was constructed. The GII.4 Sydney blockade responses showed a strong and consistent boost across the individuals postvaccination. This indicates that the GII.4 CN antigen can elicit or boost immune responses specific for newly emerged GII.4 strains. Additionally, all the GII.4 strains tested, showed GMFRs above 4 ([Table 5](#viruses-11-00392-t005){ref-type="table"}) confirming the strong coverage of the GII.4 strains by vaccination with the TAK-214 vaccine.

The strong blockade responses against GI.5 and GI.6 were significant as these genotypes are not represented in the vaccine. As with other responses that had a strong GMFR, the GI.5 blocking antibodies showed a clear majority of individuals with a boost following vaccination, even those that had negative prevaccination titers.

3.4. Medium and Low GMFR Responses {#sec3dot4-viruses-11-00392}
----------------------------------

Many of the blockade responses to VLPs had GMFRs below 4-fold ([Table 5](#viruses-11-00392-t005){ref-type="table"}). In comparison with the high GMFR responses the trend for responses against these VLPs was that fewer individuals responded to vaccination, there was no consistent boosting across the population and different patterns of responsiveness were apparent against the different VLPs. Individuals could show considerable boosting of both positive and negative preexisting responses, while other individuals did not respond. Further, a preexisting response did not necessarily guarantee boosting postvaccination ([Figure 2](#viruses-11-00392-f002){ref-type="fig"}).

GI.2-specific responses were not common prior to vaccination but boosting of some individuals was found. Boosting was not consistent across the subjects, some individuals showed very strong responses to vaccine, while others did not. Boosting was not necessarily dictated by preexisting responses since some preexisting positive responses did not boost, while subjects considered negative could boost well.

The GMFR measured for GII.17 (2015) VLPs was similar to GI.2, but the pattern differed slightly. For GII.17 (2015) responses, the fold rises were not as high among individuals, but more individuals responded. As a result, more subjects had measurable levels of blocking antibodies to GII.17 (2015) than GI.2.

The pattern of responses to GII.6 shown in [Figure 2](#viruses-11-00392-f002){ref-type="fig"} differ from the GI.2 and GII.17 (2015) responses. GII.6 blocking antibodies were common prior to vaccination, and although the levels increased they only rose slightly postvaccination, with a few individuals showed very strong boosting. The large decrease in blocking titers for the paired sample (grey squares) in the NOR-201 trial might be explained by an infection with a GII.6 strain just prior to the first sampling. Although the GMFR calculated for GII.6 response was low, the postvaccination titers indicate that most individuals had a positive level of antibodies to GII.6, and for this situation the GMFR alone does not fully reflect the GII.6 antibody response.

4. Discussion {#sec4-viruses-11-00392}
=============

An important characteristic of a broadly efficacious norovirus vaccine will be the ability of the vaccine to generate, or boost, responses against the numerous norovirus strains and genotypes that exist. These studies can shed light into the potential of the vaccine to protect against norovirus genotypes that are in circulation, and to newly emerging strains; especially those of the GII.4 genotype. Previous testing of samples from clinical studies of the Takeda norovirus vaccine candidate TAK-214 have found strong responses against vaccine antigens and, in addition, evidence for cross-reactivity against nonvaccine genotypes and strains \[[@B20-viruses-11-00392],[@B33-viruses-11-00392],[@B35-viruses-11-00392]\]. We have sought to extend these investigations with a more comprehensive evaluation of the breadth of blocking antibody responses.

The VLPs selected for testing were meant to represent the most recent nonvaccine strains from as many representative genotypes as possible. It would be impossible to capture information against all the norovirus genotypes because several VLP types do not bind PGM, and full-length VP1 sequences are missing for several genotypes. However, the panel used for testing here is the largest to date that captures blocking activity against a wide range of different genotypes and strains. The panel has many strains within the GII.4 genotype because of the historical importance of the GII.4 viruses in causing disease and the ability to evolve into new strains. For the other genotypes, Parra et al. \[[@B12-viruses-11-00392]\] suggest that their evolution may be static with only small changes in the sequences over time. Thus, having only a single strain of VLP from these genotypes should be representative of the genotype. For this reason, we feel that the coverage that the panel of VLPs provides will be a reasonable assessment of the breadth of blockade responses to norovirus.

With the exception of the two vaccine antigens, which were produced in insect cells, the VLPs chosen for the panel were expressed in mammalian cells using an adenovirus vector system. Lindesmith et al. \[[@B41-viruses-11-00392]\] have found that there were differences in the binding of antibodies to VLPs expressed from mammalian and insect cells, even though the sequences were the same. The difference in binding was thought to be the result of a higher flexibility of the mammalian expressed VLPs. A more flexible VLP may expose hidden epitopes and potentially allow more antibody populations to bind than to VLPs expressed in insect cells. We have also found differences in binding with two different strains of VLPs (GI.3 and GII.4 2012) and side by side comparisons found higher blocking titers to the mammalian-expressed VLPs. Given the possibility that assays with mammalian VLPs may be able to detect additional antibody populations we have used mammalian-expressed VLPs exclusively for all nonvaccine VLPs in our panel.

As new VLPs were generated and tested, several were found to have erratic behavior under what had been standard conditions. An extensive investigation of buffer and assay conditions for each VLP was performed to ensure that all blockade assays were optimized. An antibody response generated from vaccination or infection would contain many antibody populations that recognize the multiple epitopes of the immunizing or infecting strain. However, against a different strain, with a different amino acid sequence, only a fraction of the antibody response would be expected to cross-react because of the absence of some epitopes, and sequence differences of other epitopes that would reduce the strength of binding. These cross-reactive antibodies would be expected to contribute to protection against diverse strains. Antibody responses generated by Cervarix®---a VLP-based vaccine against Human Papilloma Virus (HPV)---were found to be 100 to 1000 times lower against nonvaccine strains than against vaccine antigens even though protection was found against the nonvaccine strains \[[@B44-viruses-11-00392]\].

With the panel of blockade assays available, samples from two vaccine clinical trials were tested to determine the breadth and strength of responses before and after vaccination, and the potential influence of MPL. Differences were observed in the levels of preexisting blocking antibody among individuals, indicating a range of exposure histories. Following vaccination, variability was also found in the strength and breadth of responses of individuals to vaccination. Further studies are required to more fully understand how preexisting responses may influence vaccination or the immunological relatedness of the genotypes that could predict vaccine coverage or assess the potential benefit of additional VLPs. Previous analysis of clinical samples had found that MPL does not enhance the magnitude of immune responses to vaccine \[[@B33-viruses-11-00392]\], and the work described here was meant to examine further if MPL influenced the breadth or character of the response to vaccine. No consistent differences were found in the strength or the breadth of responses when compared between the NOR-201 (MPL in vaccine) and NOR-210 (no MPL in vaccine) trials. Additionally, measuring IgG subclass levels for the GI.1 and GII.4 CN positive antibodies in these same samples did not show any changes in the ratios of the different IgG subclasses that may be expected if an adjuvant redirects the antibody response. These data indicate that addition of MPL is not required for effective vaccination in adults.

Levels of blocking antibodies have been identified as correlates of protection against norovirus disease \[[@B29-viruses-11-00392],[@B32-viruses-11-00392]\]. We are unable to directly compare the blocking titers measured in this work against previous studies because of assay differences. However, as in the case with the HPV vaccine \[[@B43-viruses-11-00392]\], the protective level of functional antibodies to nonvaccine VLPs may be considerably less than against vaccine antigens. Thus, even though the GMTs listed in [Table 4](#viruses-11-00392-t004){ref-type="table"} against the nonvaccine VLPs in the panel may be lower than to GI.1 and GII.4 CN, they could still be protective. Efficacy studies will be needed to define a true level of protection against nonvaccine genotypes.

One of the interesting results was how widespread the boosting was across all genotypes, suggesting that considerable cross-reactivity may be present. For the vaccine genotypes, the boosting was clear and consistent among individuals, especially across the GII.4 strains. Strong boosting of the GI.5 and GI.6 blocking antibodies also suggests a high degree of immunological relatedness with vaccine antigens. However, some individuals responded very strongly even when overall there was less than 4-fold rise and no consistent boosting among individuals. It will be of interest to identify why some individuals responded so well, and which epitopes they may be recognizing. Further dissection of these responses by depletion analyses and by evaluating monoclonal antibodies are being pursued to better define the epitopes that may be responsible for cross reactive blocking responses. Several blocking epitopes have been identified \[[@B45-viruses-11-00392],[@B46-viruses-11-00392]\] and epitope-specific reagents may be better able to dissect the blocking antibody populations after vaccination, and possibly relate specific epitopes of most importance to protection against disease. Although cross-reactive epitopes may be present in norovirus particles, antibodies to these will not necessarily be expanded due to infection, or vaccination, since stronger type-specific antibodies can dominate the immune response. Repeated exposures to different variants of an antigen during chronic infection are believed to enhance cross-reactive responses, as suggested for the appearance of broadly neutralizing antibodies against HIV \[[@B47-viruses-11-00392]\]. This sequential exposure to the various norovirus genotypes during childhood may lead to development of protective cross-reactive antibodies in adults \[[@B48-viruses-11-00392]\]. Identifying these cross-reactive epitopes in adults could then lead to the design of antigens or vaccination strategies that would favor cross-reactivity and enhance the protective capability of vaccines.
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viruses-11-00392-t0A1_Table A1

###### 

Strain-specific information.

                             VLP     Detection Antibody   
  --------------- ---------- ------- -------------------- -----
  GI.1 (1968)     M87661     0.075   GI.1 (1968)          6.0
  GI.2 (2013)     KF306212   0.3     GI.2 (2013)          6.0
  GI.3 (2007)     FJ711164   0.1     GI.3 (2007)          6.0
  GI.4 (2008)     GQ413970   0.1     GI.4 (2008)          6.0
  GI.5 (2013)     KJ402295   0.15    GI.5 (2013)          6.0
  GI.6 (2003)     KC998959   0.1     GI.6 (2003)          6.0
  GI.7 (2010)     JN899243   0.1     GI.7 (2010)          6.0
  GII.3 (2011)    KC597140   0.1     GII.3 (2011)         6.0
  GII.4 (CN)      N/A        0.1     GII.4 (CN)           10
  GII.4 (2002)    ABY27560   0.1     GII.4 (CN)           10
  GII.4 (2006a)   ABL74391   0.075   GII.4 (CN)           10
  GII.4 (2006b)   ABL74395   0.1     GII.4 (CN)           10
  GII.4 (2009)    GU445325   0.1     GII.4 (CN)           10
  GII.4 (2012)    JX459908   0.1     GII.4 (2012)         6.0
  GII.6 (2012)    AB818400   0.15    GII.6 (2012)         6.0
  GII.12 (2010)   KP064099   0.1     GII.12 (2010)        6.0
  GII.17 (1978)   JN699043   0.15    GII.17 (1978)        6.0
  GII.17 (2014)   LC043139   0.075   GII.17 (2014)        6.0
  GII.17 (2015)   KP698931   0.075   GII.17 (2015)        6.0
  GIV.1 (2012)    AFN61315   0.15    GIV.1 (2012)         6.0

viruses-11-00392-t0A2_Table A2

###### 

Blockade titers measured in sera from subjects enrolled in the NOR-201 clinical trial.

                    GI.1   GI.2   GI.3   GI.4   GI.5   GI.6   GI.7   GII.3   GII.4   GII.4   GII.4   GII.4   GII.4   GII.4   GII.6   GII.12   GII.17   GII.17   GII.17   GIV.1
  ----- ---- ------ ------ ------ ------ ------ ------ ------ ------ ------- ------- ------- ------- ------- ------- ------- ------- -------- -------- -------- -------- -------
  201   1    Pre    \<30   \<30   \<30   \<30   \<30   \<30   98     226     104     182     301     83      \<30    105     142     \<30     56       \<30     \<30     \<30
  201   1    Post   179    81     112    \<30   659    73     1197   293     2698    3788    5318    1248    121     1131    250     \<30     168      56       73       \<30
  201   2    Pre    46     \<30   \<30   178    122    66     72     101     134     334     543     106     254     130     93      42       174      128      82       \<30
  201   2    Post   2132   \<30   \<30   198    239    141    89     155     806     2025    2872    179     252     272     111     49       186      125      94       \<30
  201   3    Pre    \<30   \<30   44     \<30   \<30   69     \<30   60      50      81      139     20      \<30    \<30    205     37       104      62       76       \<30
  201   3    Post   765    \<30   110    \<30   1076   2421   307    172     9267    9677    12578   4424    288     4934    874     115      1313     691      351      36
  201   4    Pre    44     48     286    \<30   67     \<30   108    465     650     1540    1738    546     66      118     846     185      1123     484      182      \<30
  201   4    Post   2198   100    320    \<30   155    \<30   151    480     1020    2728    3727    756     184     211     962     191      1040     396      193      \<30
  201   5    Pre    \<30   \<30   \<30   \<30   \<30   \<30   \<30   \<30    \<30    \<30    \<30    \<30    \<30    \<30    \<30    \<30     58       \<30     \<30     \<30
  201   5    Post   238    \<30   \<30   \<30   \<30   \<30   \<30   \<30    116     143     135     72      \<30    72      \<30    \<30     404      127      93       \<30
  201   6    Pre    171    46     56     \<30   237    60     290    57      91      241     352     55      49      32      185     617      319      181      100      \<30
  201   6    Post   94     151    97     228    1360   405    589    317     3491    5505    7292    403     74      601     522     769      693      241      168      \<30
  201   7    Pre    48     122    332    50     314    \<30   386    74      293     564     829     491     142     549     196     132      126      \<30     \<30     \<30
  201   7    Post   1292   127    293    55     330    \<30   349    113     847     2011    2766    1051    343     918     205     105      134      44       31       \<30
  201   8    Pre    \<30   \<30   \<30   \<30   \<30   \<30   \<30   \<30    73      242     324     56      \<30    63      145     \<30     123      \<30     \<30     \<30
  201   8    Post   199    \<30   \<30   \<30   125    306    \<30   \<30    1160    2805    3864    929     258     1210    159     \<30     191      79       37       \<30
  201   9    Pre    \<30   \<30   142    \<30   \<30   \<30   \<30   \<30    101     277     392     91      95      104     \<30    \<30     \<30     94       \<30     \<30
  201   9    Post   135    \<30   308    \<30   147    \<30   144    \<30    910     3292    4081    1310    735     1421    \<30    \<30     204      95       \<30     \<30
  201   10   Pre    \<30   93     \<30   122    81     157    \<30   174     \<30    \<30    \<30    \<30    179     \<30    644     87       599      300      179      208
  201   10   Post   430    622    \<30   1063   3181   2550   234    263     108     652     617     881     128     127     1602    375      2563     1273     734      199
  201   11   Pre    \<30   \<30   \<30   37     \<30   \<30   \<30   \<30    36      130     183     \<30    \<30    \<30    \<30    \<30     \<30     45       \<30     \<30
  201   11   Post   224    \<30   \<30   655    703    142    \<30   66      1302    3195    4261    451     131     415     \<30    \<30     72       79       \<30     \<30
  201   12   Pre    \<30   \<30   \<30   81     34     \<30   \<30   88      362     801     1134    217     107     296     301     136      183      85       53       \<30
  201   12   Post   789    135    \<30   3591   4683   1039   204    146     666     1290    1671    392     184     323     343     164      199      83       75       \<30
  201   13   Pre    \<30   70     \<30   \<30   \<30   \<30   \<30   \<30    359     1031    1311    382     173     350     \<30    \<30     \<30     \<30     \<30     \<30
  201   13   Post   362    554    57     \<30   144    34     \<30   \<30    623     1770    2352    805     381     519     \<30    \<30     \<30     \<30     \<30     \<30
  201   14   Pre    125    \<30   196    \<30   88     \<30   \<30   30      397     1060    1406    660     301     492     88      114      42       \<30     \<30     \<30
  201   14   Post   2605   \<30   205    58     161    44     \<30   102     597     1426    2019    951     506     684     88      165      61       \<30     \<30     \<30
  201   15   Pre    \<30   46     40     \<30   537    \<30   67     457     306     1130    1190    268     IND     397     3224    215      933      210      362      \<30
  201   15   Post   186    459    422    318    3664   1755   733    62      641     1349    1484    767     356     925     307     333      1100     134      142      \<30
  201   16   Pre    \<30   \<30   \<30   \<30   68     \<30   \<30   165     236     658     895     146     155     244     177     42       610      \<30     \<30     \<30
  201   16   Post   163    \<30   \<30   \<30   673    420    66     190     636     1577    2004    385     281     367     217     147      1193     61       53       \<30
  201   17   Pre    43     \<30   106    \<30   234    \<30   \<30   \<30    47      124     188     66      \<30    32      54      67       143      \<30     \<30     \<30
  201   17   Post   2395   \<30   135    \<30   367    80     \<30   \<30    329     851     1180    607     351     444     106     84       285      38       61       \<30
  201   18   Pre    \<30   \<30   \<30   \<30   \<30   49     \<30   \<30    106     473     697     166     134     62      146     74       102      97       46       \<30
  201   18   Post   437    \<30   \<30   \<30   502    193    \<30   \<30    636     1653    2283    485     406     242     214     117      586      138      100      \<30
  201   19   Pre    49     165    233    \<30   830    181    499    78      112     354     486     226     169     156     310     127      1448     149      168      \<30
  201   19   Post   2922   146    211    \<30   869    225    479    380     2351    5424    7353    1820    833     1980    630     287      2306     423      649      \<30
  201   20   Pre    \<30   \<30   145    104    \<30   \<30   \<30   \<30    102     371     523     63      \<30    90      51      103      87       \<30     \<30     \<30
  201   20   Post   264    1100   226    2561   1699   118    84     \<30    715     1734    2656    326     161     340     69      110      118      \<30     \<30     \<30
  201   21   Pre    38     \<30   \<30   176    370    44     61     35      204     629     925     257     130     277     156     94       107      37       \<30     \<30
  201   21   Post   183    150    \<30   608    4540   813    675    118     682     1976    2638    1121    576     921     953     189      360      137      92       \<30
  201   22   Pre    \<30   93     149    \<30   52     120    471    150     91      205     294     102     \<30    104     186     124      289      133      80       \<30
  201   22   Post   296    503    181    \<30   891    971    583    1433    3555    4572    6781    3082    722     1336    717     635      3631     568      839      99
  201   23   Pre    \<30   \<30   83     \<30   \<30   \<30   \<30   \<30    305     807     1053    474     391     367     35      \<30     107      36       \<30     \<30
  201   23   Post   \<30   \<30   \<30   \<30   138    1170   \<30   31      1939    4237    6642    744     509     507     104     \<30     227      51       40       \<30
  201   24   Pre    \<30   \<30   72     \<30   293    \<30   \<30   60      168     336     489     194     \<30    147     65      133      193      \<30     \<30     \<30
  201   24   Post   \<30   44     84     \<30   471    72     50     66      627     1466    2336    547     150     336     83      189      243      \<30     \<30     \<30
  201   25   Pre    \<30   \<30   \<30   \<30   \<30   71     \<30   264     336     705     958     341     303     596     469     119      777      308      163      \<30
  201   25   Post   \<30   \<30   \<30   \<30   338    858    \<30   254     767     1542    1728    832     382     986     508     115      977      388      216      \<30

Blockade titers below the assigned lower limit of quantitation of 30 were given a value of \<30. IND represents indeterminant titers in which sample titer could not be calculated for both the initial and repeat testing.

viruses-11-00392-t0A3_Table A3

###### 

Blockade titers measured in sera from subjects enrolled in the NOR-210 clinical trial.

                    GI.1   GI.2   GI.3   GI.4   GI.5   GI.6   GI.7   GII.3   GII.4   GII.4   GII.4   GII.4   GII.4   GII.4   GII.6   GII.12   GII.17   GII.17   GII.17   GIV.1
  ----- ---- ------ ------ ------ ------ ------ ------ ------ ------ ------- ------- ------- ------- ------- ------- ------- ------- -------- -------- -------- -------- -------
  210   26   Pre    \<30   179    98     \<30   280    \<30   259    118     297     889     1467    1077    187     350     1440    518      1154     408      125      \<30
  210   26   Post   310    585    226    79     2654   397    1875   \<301   827     1823    2632    1696    230     811     1251    493      1378     458      147      \<30
  210   27   Pre    \<30   \<30   342    \<30   372    \<30   198    217     \<30    80      100     \<30    \<30    \<30    62      143      103      34       \<30     \<30
  210   27   Post   77     \<30   514    \<30   1090   213    367    351     1748    2625    3443    548     198     193     132     203      188      68       52       \<30
  210   28   Pre    85     86     53     65     166    \<30   122    64      \<30    74      101     \<30    52      \<30    139     \<30     101      106      32       \<30
  210   28   Post   612    352    \<30   699    962    88     185    58      1526    4310    5514    538     309     375     253     \<30     303      123      89       78
  210   29   Pre    690    540    444    1577   864    593    719    276     79      448     619     520     498     180     359     \<30     164      682      429      264
  210   29   Post   1464   874    1265   2105   3183   1684   3111   408     10666   15312   20102   997     779     789     376     67       459      576      350      246
  210   30   Pre    \<30   \<30   \<30   \<30   \<30   \<30   \<30   \<30    364     928     1282    427     194     360     \<30    \<30     102      \<30     \<30     30
  210   30   Post   199    \<30   \<30   \<30   \<30   \<30   \<30   \<30    2240    4379    5835    2548    926     1896    80      38       206      \<30     \<30     65
  210   31   Pre    \<30   98     66     166    81     411    \<30   \<30    \<30    \<30    \<30    \<30    \<30    \<30    \<30    \<30     134      54       50       \<30
  210   31   Post   525    419    161    1311   2247   1384   112    1091    275     104     118     129     \<30    303     369     211      1529     530      468      \<30
  210   32   Pre    \<30   \<30   \<30   \<30   295    \<30   105    \<30    \<30    100     129     49      \<30    32      95      \<30     118      \<30     31       \<30
  210   32   Post   3440   \<30   \<30   \<30   522    39     171    200     3707    6667    8305    3587    1217    2735    134     51       342      93       116      \<30
  210   33   Pre    \<30   \<30   70     \<30   \<30   \<30   129    152     335     577     950     173     34      56      40      \<30     35       \<30     \<30     \<30
  210   33   Post   392    157    253    \<30   1671   601    690    181     2578    4770    6373    1039    678     1066    93      \<30     318      \<30     69       \<30
  210   34   Pre    \<30   \<30   90     504    \<30   119    \<30   88      \<30    \<30    \<30    \<30    \<30    \<30    34      34       148      \<30     47       \<30
  210   34   Post   311    1433   165    4994   1643   579    213    413     96      81      92      95      \<30    122     58      194      386      84       190      \<30
  210   35   Pre    \<30   \<30   \<30   \<30   \<30   90     \<30   \<30    74      159     227     90      48      84      50      \<30     54       \<30     \<30     \<30
  210   35   Post   176    \<30   \<30   \<30   203    563    \<30   41      557     1106    1616    668     340     581     74      \<30     171      \<30     \<30     \<30
  210   36   Pre    \<30   \<30   \<30   \<30   \<30   260    \<30   \<30    405     1142    1972    112     89      65      206     121      66       \<30     \<30     \<30
  210   36   Post   203    \<30   \<30   \<30   90     1031   \<30   \<30    2209    6022    7565    1322    752     1114    483     259      1387     186      174      \<30
  210   37   Pre    125    58     314    \<30   536    76     \<30   100     103     241     356     75      310     71      130     167      148      32       50       \<30
  210   37   Post   4379   142    370    89     1145   141    44     123     6345    14297   24490   2048    1067    1138    164     267      235      39       60       \<30
  210   38   Pre    88     104    73     50     423    \<30   \<30   234     137     400     460     330     152     97      268     100      497      117      55       \<30
  210   38   Post   278    455    300    199    4583   346    498    439     777     2090    3547    999     362     329     385     169      791      139      72       \<30
  210   39   Pre    \<30   \<30   \<30   \<30   \<30   101    \<30   \<30    \<30    59      72      \<30    \<30    \<30    \<30    \<30     \<30     \<30     \<30     \<30
  210   39   Post   \<30   \<30   \<30   \<30   \<30   212    \<30   \<30    2283    5403    6935    333     200     332     51      82       110      \<30     \<30     \<30
  210   40   Pre    \<30   56     \<30   \<30   \<30   \<30   \<30   174     230     1328    2517    459     311     110     449     \<30     661      \<30     \<30     \<30
  210   40   Post   2381   94     \<30   \<30   212    \<30   \<30   218     2427    6321    9443    693     465     303     481     43       724      37       37       \<30
  210   41   Pre    \<30   \<30   168    \<30   \<30   61     149    211     \<30    33      71      \<30    \<30    \<30    264     222      411      103      \<30     \<30
  210   41   Post   \<30   \<30   294    \<30   132    119    247    246     3317    6645    9385    1157    473     388     396     307      521      168      90       \<30
  210   42   Pre    \<30   \<30   \<30   \<30   70     \<30   \<30   \<30    920     1495    3847    1820    738     597     \<30    \<30     \<30     37       \<30     \<30
  210   42   Post   350    668    173    \<30   1699   383    169    \<30    1549    6600    7032    3434    1618    1361    124     \<30     231      36       \<30     \<30
  210   43   Pre    \<30   \<30   \<30   \<30   103    \<30   \<30   86      241     458     556     425     218     315     154     219      320      139      86       \<30
  210   43   Post   402    181    117    \<30   3156   720    296    104     1235    2287    4880    1922    833     1244    196     317      613      163      119      \<30
  210   44   Pre    \<30   \<30   \<30   182    190    \<30   \<30   58      86      386     528     31      \<30    \<30    110     241      79       \<30     \<30     \<30
  210   44   Post   768    82     \<30   2951   3796   432    98     67      3682    4034    11418   1292    1071    1436    131     283      144      \<30     \<30     \<30
  210   45   Pre    \<30   \<30   \<30   \<30   \<30   91     \<30   265     274     1270    2231    518     195     425     195     602      546      195      176      \<30
  210   45   Post   123    \<30   \<30   \<30   \<30   208    \<30   296     1532    7547    7177    1469    365     1377    277     644      953      342      377      \<30
  210   46   Pre    90     61     \<30   \<30   \<30   \<30   \<30   \<30    141     141     211     36      \<30    \<30    \<30    \<30     112      \<30     \<30     \<30
  210   46   Post   1660   68     \<30   \<30   \<30   \<30   \<30   \<30    786     1297    2483    99      \<30    46      \<30    \<30     179      \<30     \<30     \<30
  210   47   Pre    \<30   210    \<30   \<30   \<30   \<30   \<30   \<30    \<30    \<30    \<30    \<30    \<30    \<30    157     \<30     82       174      \<30     \<30
  210   47   Post   763    367    \<30   \<30   \<30   34     \<30   476     1794    663     663     \<30    659     \<30    160     \<30     75       112      \<30     \<30
  210   48   Pre    226    304    284    293    262    107    274    89      97      346     334     208     168     117     153     481      108      245      130      86
  210   48   Post   147    129    403    157    521    235    641    263     2405    4927    8090    1335    1047    1484    265     478      420      317      207      61
  210   49   Pre    37     71     435    \<30   725    135    634    94      231     895     1325    200     IND     190     152     259      310      106      101      \<30
  210   49   Post   4327   154    550    49     1209   323    889    109     1681    3720    5461    1684    1624    1398    176     268      389      117      132      \<30

Blockade titers below the assigned lower limit of quantitation of 30 were given a value of \<30. IND represents indeterminant titers in which sample titer could not be calculated for both the initial and repeat testing.

![Blockade titers specific for GI.1 (1968), GII.4 (CN), GII.4 (2012), and GI.5 (2013) measured in individual sera before and after vaccination with TAK-214 in the NOR-201 and NOR-210 clinical trials. The subjects tested from NOR-201 were given vaccine that contained MPL adjuvant and subjects in NOR-210 received vaccine without MPL. Individual subjects are different colors and matched sera results are connected by solid lines. The bars in the background represent the geometric mean titer of the subjects. Samples below the assay lower limit of quantitation of 30 are assigned a value of 15.](viruses-11-00392-g001){#viruses-11-00392-f001}

![Blockade Titers Specific for GI.2 (2013), GII.17 (2015), and GII.6 (2012) measured in individual sera before and after vaccination with TAK-214 in the NOR-201 and NOR-210 clinical trials. The subjects tested from NOR-201were given vaccine that contained MPL adjuvant and subjects in NOR-210 received vaccine without MPL. Individual subjects are different colors and matched sera results are connected by solid lines. The bars in the background represent the geometric mean titer of the subjects. Samples below the assay lower limit of quantitation of 30 are assigned a value of 15.](viruses-11-00392-g002){#viruses-11-00392-f002}

viruses-11-00392-t001_Table 1

###### 

Pig gastric mucin (PGM) binding by virus-like particles (VLPs) under different conditions of temperature (22 °C or 37 °C), buffer pH (6.5, 7.0 and 7.5), and skim milk percent (0% and 5%).

                  Buffer pH 6.5   Buffer pH 7.0   Buffer pH 7.5                                              
  --------------- --------------- --------------- --------------- ---- ----- ---- ----- ---- ---- ---- ----- ----
  GI.1 (1968)     78 ^1^          38              100             61   79    32   96    49   83   38   97    57
  GI.2 (2013)     59              42              100             57   49    38   77    47   54   41   81    50
  GI.3 (2007)     68              60              95              91   72    48   96    81   72   58   100   81
  GI.4 (2008)     83              20              100             22   76    13   95    14   75   21   93    25
  GI.5 (2013)     81              45              100             33   63    37   95    38   47   32   43    35
  GI.6 (2003)     91              75              71              42   100   66   44    22   99   89   18    8
  GI.7 (2010)     74              28              100             33   38    29   53    31   80   35   98    41
  GII.3 (2011)    68              60              95              91   72    48   96    81   72   58   100   81
  GII.4 (CN)      79              55              100             83   76    56   79    76   79   63   33    62
  GII.4 (2009)    76              59              98              72   77    61   100   74   74   66   97    86
  GII.4 (2012)    68              60              95              91   72    48   96    81   72   58   100   81
  GII.6 (2012)    77              53              100             65   79    50   98    55   70   59   92    68
  GII.17 (1978)   80              67              100             89   66    62   83    75   74   69   75    74
  GII.17 (2014)   85              53              96              68   86    57   95    72   89   64   100   83
  GII.17 (2015)   87              66              98              90   81    55   98    86   80   57   100   88
  GIV.1 (2012)    89              33              51              13   100   24   74    14   69   27   54    15

^1^ Values are relative percent binding with strongest measures assigned a value of 100%. Red shading represents the strongest binding and green the weakest binding.

viruses-11-00392-t002_Table 2

###### 

Titer comparisons from VLP blockade assays performed under different conditions of primary incubation (18 h and 1 h), PGM binding temperature (22 °C and 37 °C), and assay buffer pH (6.5 and 7.5).

  ----------------------------------------------------------------------------------------------------
                  Primary Incubation   PGM Incubation   Assay Buffer pH   Final Conditions\    
                                                                          (All 18 h Primary)   
  --------------- -------------------- ---------------- ----------------- -------------------- -------
  GI.1 (1968)     2.0                  1.1              1.0               Both                 37 °C

  GI.2 (2013)     1.3                  1.1              1.0               Both                 37 °C

  GI.3 (2007)     1.3                  1.0              0.8               Both                 37 °C

  GI.4 (2008)     1.8                  1.2              1.1               Both                 37 °C

  GI.5 (2013)     1.8                  1.9              pH 7.5 Fail       pH 6.5               37 °C

  GI.6 (2003)     1.1                  37 °C Fail       pH 7.5 Fail       pH 6.5               22 °C

  GI.7 (2010)     2.5                  1.3              0.6               pH 7.5               37 °C

  GII.3 (2011)    3.7                  1.0              1.0               Both                 37 °C

  GII.4 (CN)      1.3                  1.5              pH 7.5 Fail       pH 6.5               37 °C

  GII.4 (2002)    1.1                  1.1              0.9               pH 6.5               37 °C

  GII.4 (2006a)   1.4                  1.2              0.8               pH 6.5               37 °C

  GII.4 (2006b)   1.2                  1.0              pH 7.5 Fail       pH 6.5               37 °C

  GII.4 (2009)    1.6                  1.3              0.9               Both                 37 °C

  GII.4 (2012)    1.4                  1.5              0.5               pH 7.5               37 °C

  GII.6 (2012)    1.4                  1.5              pH 7.5 Fail       pH 6.5               37 °C

  GII.12 (2010)   1.1                  2.2              pH 7.5 Fail       pH 6.5               37 °C

  GII.17 (1978)   2.3                  1.7              0.4               pH 7.5               37 °C

  GII.17 (2014)   3.0                  1.5              0.5               pH 7.5               37 °C

  GII.17 (2015)   3.0                  2.0              0.5               pH 7.5               37 °C

  GIV.1 (2012)    1.0                  37 °C Fail       pH 7.5 Fail       pH 6.5               22 °C
  ----------------------------------------------------------------------------------------------------

viruses-11-00392-t003_Table 3

###### 

Percentage of subjects with positive blockade titers before and after vaccination.

                  Prevaccination % Positive   Postvaccination % Positive                    
  --------------- --------------------------- ---------------------------- ---- ----- ----- -----
  GI.1 (1968)     32                          29                           31   88    92    90
  GI.2 (2013)     32                          46                           39   52    67    59
  GI.3 (2007)     52                          50                           51   56    54    55
  GI.4 (2008)     28                          29                           29   40    42    41
  GI.5 (2013)     56                          54                           55   96    79    88
  GI.6 (2003)     36                          46                           41   84    88    86
  GI.7 (2010)     36                          38                           37   64    67    65
  GII.3 (2011)    64                          63                           63   72    79    76
  GII.4 (CN)      92                          67                           80   100   100   100
  GII.4 (2002)    92                          88                           90   100   100   100
  GII.4 (2006a)   92                          88                           90   100   100   100
  GII.4 (2006b)   88                          71                           80   100   96    98
  GII.4 (2009)    60                          58                           62   96    88    92
  GII.4 (2012)    84                          63                           73   100   96    98
  GII.6 (2012)    84                          79                           82   84    96    90
  GII.12 (2010)   72                          50                           61   72    75    73
  GII.17 (1978)   88                          92                           90   96    100   98
  GII.17 (2014)   60                          58                           59   84    75    80
  GII.17 (2015)   44                          50                           47   76    71    73
  GIV.1 (2012)    4                           13                           8    12    17    14

viruses-11-00392-t004_Table 4

###### 

Geometric mean titers before and after vaccination.

                  Prevaccination GMTs   Postvaccination GMTs                                                            
  --------------- --------------------- ---------------------- ---------------- ------------------- ------------------- -------------------
  GI.1 (1968)     23 (17--32)           28 (18--44)            25 (20--33)      308 (163--580)      397 (210--752)      349 (226--538)
  GI.2 (2013)     25 (18--36)           39 (24--64)            31 (23--42)      59 (32--111)        101 (52--195)       77 (50--120)
  GI.3 (2007)     44 (27--71)           48 (27--83)            46 (32--65)      58 (34--100)        76 (39--148)        66 (44--100)
  GI.4 (2008)     25 (17--36)           33 (18--59)            29 (20--40)      57 (26--124)        62 (26--144)        59 (34--103)
  GI.5 (2013)     56 (32--99)           70 (36--135)           62 (41--95)      509 (292--889)      417 (177--981)      462 (283--752)
  GI.6 (2003)     27 (19--39)           42 (25--70)            34 (25--46)      194 (97--386)       207 (114--373)      200 (129--310)
  GI.7 (2010)     35 (21--60)           42 (23--75)            38 (26--56)      91 (48--175)        117 (56--243)       103 (64--165)
  GII.3 2011)     54 (33--88)           58 (36--94)            56 (40--78)      86 (49--150)        118 (68--204)       100 (69--147)
  GII.4 (CN)      128 (85--192)         83 (47--148)           104 (74--146)    906 (605--1355)     1609 (1065--2433)   1200 (898--1604)
  GII.4 2002)     313 (192--511)        225 (120--424)         266 (181--392)   2030 (1441--2860)   2896 (1673--5014)   2416 (1767--3304)
  GII.4 (2006a)   428 (259--707)        317 (158--636)         370 (245--558)   2675 (1836--3897)   4079 (2296--7245)   3289 (2356--4591)
  GII.4 (2006b)   121 (75--196)         99 (51--192)           110 (74--162)    711 (503--1006)     755 (436--1308)     732 (537--999)
  GII.4 (2009)    64 (38--108)          64 (36--117)           64 (44--94)      256 (179--365)      378 (210--679)      310 (222--432)
  GII.4 (2012)    110 (67--181)         62 (36--108)           83 (58--120)     566 (389--825)      543 (323--914)      555 (408--754)
  GII.6 (2012)    124 (72--216)         94 (56--159)           108 (75--157)    178 (100--318)      176 (119--260)      177 (126--248)
  GII.12 (2010)   62 (40--96)           55 (30--101)           58 (41--83)      89 (53--152)        98 (56--171)        93 (64--135)
  GII.17 (1978)   150 (88--257)         134 (85--212)          142 (101--200)   361 (212--617)      368 (261--518)      364 (268--496)
  GII.17 (2014)   52 (32--85)           50 (29--84)            51 (36--72)      103 (62--173)       80 (48--136)        91 (64--131)
  GII.17 (2015)   37 (23--57)           35 (23--53)            36 (26--48)      76 (45--128)        68 (42--111)        72 (51--102)
  GIV.1 (2012)    17 (13--21)           19 (14--25)            18 (15--21)      19 (14--24)         20 (15--28)         19 (16--24)

viruses-11-00392-t005_Table 5

###### 

Geometric mean fold-rise of titers after vaccination.

                  NOR-201            NOR-210             Both
  --------------- ------------------ ------------------- ------------------
  GI.1 (1968)     13.5 (7.8--23.3)   14.4 (7.6--27.5)    14.0 (9.3--20.9)
  GI.2 (2013)     2.3 (1.5--3.8)     2.7 (1.6--4.5)      2.5 (1.8--3.5)
  GI.3 (2007)     1.4 (1.1--1.9)     1.6 (1.2--2.2)      1.5 (1.3--1.9)
  GI.4 (2008)     2.3 (1.3--3.9)     1.9 (1.3--2.9)      2.1 (1.5--2.9)
  GI.5 (2013)     9.2 (5.0--17.2)    6.1 (3.3--11.2)     7.5 (4.9--11.5)
  GI.6 (2003)     6.9 (3.8--12.6)    4.9 (2.9--8.2)      5.8 (4.0--8.6)
  GI.7 (2010)     2.5 (1.6--4.0)     2.8 (1.8--4.5)      2.7 (1.9--3.7)
  GII.3 (2011)    1.7 (1.3--2.3)     1.9 (1.2--3.2)      1.8 (1.4--2.4)
  GII.4 (CN)      7.2 (4.4--11.9)    19.7 (10.3--37.5)   11.8 (7.8--17.9)
  GII.4 (2002)    6.4 (3.9--10.6)    12.7 (7.5--21.4)    9.0 (6.2--12.9)
  GII.4 (2006a)   6.0 (3.6--9.8)     13.1 (7.7--22.3)    8.7 (6.0--12.7)
  GII.4 (2006b)   5.8 (3.3--10.0)    7.9 (4.7--13.3)     6.7 (4.7--9.7)
  GII.4 (2009)    3.8 (2.3--6.1)     5.3 (2.9--9.8)      4.5 (3.1--6.5)
  GII.4 (2012)    5.0 (2.8--8.8)     8.5 (5.2--14.0)     6.5 (4.5--9.4)
  GII.6 (2012)    1.5 (1.2--1.9)     1.7 (1.2--2.4)      1.6 (1.3--2.0)
  GII.12 (2010)   1.4 (1.1--1.7)     1.7 (1.2--2.3)      1.5 (1.3--1.9)
  GII.17 (1978)   2.3 (1.6--3.3)     2.8 (1.9--4.0)      2.5 (2.0--3.3)
  GII.17 (2014)   2.0 (1.4--2.7)     1.6 (1.1--2.2)      1.8 (1.4--2.2)
  GII.17 (2015)   2.1 (1.5--2.9)     1.9 (1.3--2.6)      2.0 (1.6--2.5)
  GIV.1 (2012)    1.1 (0.9--1.3)     1.1 (0.9--1.3)      1.1 (1.0--1.2)
